Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
r-hIL-18BP (tadekinig alfa) is a recombinant human interleukin-18 binding protein inhibiting IL18. It captures excess free IL-18 mimicking the normal physiological situation, and therefore represents a well differentiated approach for the treatment of IL-18-opathies.
Lead Product(s): Tadekinig Alfa
Therapeutic Area: Genetic Disease Product Name: r-hIL-18BP
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2023
Details:
Tadekinig alfa is a novel IL-18 binding protein in pivotal Phase 3 testing for orphan disease IL-18 driven monogenic Hemophagocytic Lymphohistiocytosis (HLH). WuXi Biologics to undertake commercial scale manufacturing to support U.S. market launch.
Lead Product(s): Tadekinig alfa
Therapeutic Area: Immunology Product Name: r-hIL-18BP
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: WuXi Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 29, 2020